BioXcel Therapeutics Ownership | Who Owns BioXcel Therapeutics?


OverviewForecastRevenueFinancialsChart

BioXcel Therapeutics Ownership Summary


BioXcel Therapeutics is owned by 44.57% institutional investors, 3.97% insiders, and 51.46% retail investors. Millennium management is the largest institutional shareholder, holding 15.86% of BTAI shares. BSO Bio Santé C is the top mutual fund, with 2.26% of its assets in BioXcel Therapeutics shares.

BTAI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioXcel Therapeutics44.57%3.97%51.46%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Millennium management1.94M15.86%$2.60M
Armistice capital1.91M15.65%$2.56M
Vanguard group292.75K2.06%$468.40K
Oaktree capital management lp241.19K1.98%$323.19K
Geode capital management230.17K1.89%$308.73K
Xtx topco113.36K1.45%$290.21K
Blackrock440.69K1.43%$564.08K
Jones financial companies lllp131.79K1.08%$166.05K
Man group96.47K0.79%$129.27K
State street92.12K0.75%$123.44K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Oaktree fund advisors42.91K0.10%$57.50K
Armistice capital1.91M0.05%$2.56M
Xtx topco113.36K0.02%$290.21K
Oaktree capital management lp241.19K0.01%$323.19K
Eversource wealth advisors1.77K0.00%$73.86K
Portfolio strategies12.18K0.00%$16.32K
Millennium management1.94M0.00%$2.60M
Wiley bros.-aintree capital80.86K0.00%$108.36K
Diversify wealth management15.00K0.00%$15.60K
Man group96.47K0.00%$129.27K

Top Buyers

HolderShares% AssetsChange
Armistice capital1.91M0.05%1.91M
Millennium management1.94M0.00%101.57K
Vanguard group292.75K-100.63K
Xtx topco113.36K0.02%89.94K
Vanguard fiduciary trust84.92K-84.92K

Top Sellers

HolderShares% AssetsChange
Blackrock440.69K--887.38K
Ameriprise financial---579.16K
Jane street group---127.50K
Bank of new york mellon---123.08K
Gsa capital partners llp---120.10K

New Positions

HolderShares% AssetsChangeValue
Armistice capital1.91M0.05%1.91M$2.56M
Vanguard fiduciary trust84.92K-84.92K$113.79K
Wiley bros.-aintree capital80.86K0.00%80.86K$108.36K
Beacon pointe advisors18.88K0.00%18.88K$25.30K
Aqr capital management14.36K-14.36K$18.38K

Sold Out

HolderChange
Mount yale investment advisors-1.00
Federation des caisses desjardins du quebec-1.00
Nelson, van denburg & campbell wealth management group-4.00
National bank of canada /fi/-6.00
Point72 (difc)-35.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202639-4.88%5,441,39553.85%447.18%18-14.29%7-
Dec 31, 202520-44.44%818,099-65.30%50.64%9-60.87%3-
Sep 30, 202516-51.52%549,847-11.04%711.29%10-33.33%1-85.71%
Jun 30, 2025323.23%613,02561.47%7797.16%14100.00%7-70.83%
Mar 31, 20251-97.92%661-99.99%-0.85%1-94.74%--100.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
BSO Bio Santé C70.00K2.26%-
Vanguard Total Stock Mkt Idx Inv55.39K1.73%-
Fidelity Growth Compy Commingled Pl O469.48K1.15%-425.27K
Vanguard US Total Market Shares ETF886.24K1.01%-1.00
Fidelity Growth Company Fund353.64K0.87%-248.67K
Vanguard Institutional Extnd Mkt Idx Tr207.34K0.77%-
Fidelity Extended Market Index125.45K0.46%19.92K
Fidelity Growth Company K6163.94K0.40%-132.22K
Fidelity Select Biotechnology90.30K0.33%-
Extended Equity Market Fund B69.31K0.26%-

Recent Insider Transactions


DateNameRoleActivityValue
May 20, 2026Yocca Frank Chief Scientific OfficerSell$7.43K
May 20, 2026Rodriguez Javier See RemarksSell$7.11K
May 20, 2026Steinhart Richard I Chief Financial OfficerSell$7.43K
May 20, 2026Mehta Vimal CEO and PresidentSell$21.11K
Dec 16, 2024O'Neill Vincent See RemarksSell$58.13

Insider Transactions Trends


DateBuySell
2026 Q2-4
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--

BTAI Ownership FAQ


Who Owns BioXcel Therapeutics?

BioXcel Therapeutics shareholders are primarily institutional investors at 44.57%, followed by 3.97% insiders and 51.46% retail investors. The average institutional ownership in BioXcel Therapeutics's industry, Biotech Stocks , is 35.75%, which BioXcel Therapeutics exceeds.

Who owns the most shares of BioXcel Therapeutics?

BioXcel Therapeutics’s largest shareholders are Millennium management (1.94M shares, 15.86%), Armistice capital (1.91M shares, 15.65%), and Vanguard group (292.75K shares, 2.06%). Together, they hold 33.57% of BioXcel Therapeutics’s total shares outstanding.

Does Blackrock own BioXcel Therapeutics?

Yes, BlackRock owns 1.43% of BioXcel Therapeutics, totaling 440.68K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 564.08K$. In the last quarter, BlackRock decreased its holdings by -887K shares, a -66.82% change.

Who is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested?

Oaktree fund advisors is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.10% of its assets in 42.91K BioXcel Therapeutics shares, valued at 57.5K$.

Who is the top mutual fund holder of BioXcel Therapeutics shares?

BSO Bio Santé C is the top mutual fund holder of BioXcel Therapeutics shares, with 2.26% of its total shares outstanding invested in 70K BioXcel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools